GALWAY, IRELAND--July 1, 2024--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--The maker of the popular Ozempic and Wegovy diabetes and weight-loss drugs, Danish pharmaceutical company Novo Nordisk A/S (NYSE:NVO) (Bagsværd, Denmark), has canceled plans for a US$2 billion expansion of its campus in Dublin, Ireland. Within this article: Details cancellation of Novo's Dublin plant expansion, rapid growth of company's Ozempic and Wegovy diabetes and weight-loss drugs, related plant expansion projects in France and Denmark
(All Fields Required)
Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.
×For More Info!
